The dual-therapy COMBO stent: a rationale for a light dual antiplatelet therapy treatment

Abstract

The COMBO stent is a new, sirolimus-eluting bioresorbable polymer, bioengineered stent. This technology combines the advantages of second-generation drug-eluting stents with the endothelial progenitor cell capture technology mediated by the anti-CD34 antibody coating on the COMBO luminal surface. This dual technology should improve vessel endothelium regeneration and may lay the biological basis for a short dual antiplatelet therapy course. As new evidence is adding on the safety and efficacy of this stent compared with first- and second-generation drug-eluting stents and across a variety of patient populations, aim of this review is to summarize available clinical experience and future perspective with this device.